Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P21583

UPID:
SCF_HUMAN

ALTERNATIVE NAMES:
Mast cell growth factor; Stem cell factor; c-Kit ligand

ALTERNATIVE UPACC:
P21583; A0AV09; A8K2Q4; B7ZLM4; Q16487; Q68DZ2; Q7M4N8; Q9UQK7

BACKGROUND:
The protein Kit ligand, with alternative names Mast cell growth factor and c-Kit ligand, is essential for various biological processes including gametogenesis and mast cell development. It activates signaling pathways that are vital for cell regulation and melanogenesis.

THERAPEUTIC SIGNIFICANCE:
Given Kit ligand's association with conditions like familial progressive hyperpigmentation and sensorineural deafness, exploring its function offers promising avenues for developing targeted therapies. Its critical role in disease mechanisms underscores the therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.